Posted by Michael Wonder on 12 Dec 2021
FDA approves NGS based companion diagnostic for EGFR exon20 insertion mutant non-small-cell lung cancer tumour tissue
9 December 2021 - Oncomine Dx Target Test now approved for 12 NSCLC targeted therapies globally.
The U.S. FDA has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic to help identify non-small-cell lung cancer patients whose tumours carry epidermal growth factor receptor Exon20 insertion mutations for potential treatment with Rybrevant (amivantamab-vmjw), Janssen Biotech's targeted therapy.
